^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    VEGFC (Vascular Endothelial Growth Factor C)

    i
    Other names: VEGFC, Vascular Endothelial Growth Factor C, Vascular Endothelial Growth Factor-Related Protein, VRP, Flt4-L, VEGF-C, FLT4 Ligand DHM, Flt4 Ligand, LMPH1D, LMPHM4
    2d
    The Impact of Tumor Microenvironmental Acidity on Bicalutamide Sensitivity in Prostate Cancer Cells. (PubMed, Prostate Cancer)
    The efficacy of bicalutamide in prostate cancer cells is significantly influenced by extracellular pH. The drug exerts stronger cytotoxic, antimigratory, and proapoptotic effects at physiological pH (7.4) compared with acidic conditions (6.8).
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • BAX (BCL2-associated X protein) • VEGFC (Vascular Endothelial Growth Factor C) • CDH2 (Cadherin 2) • SNAI1 (Snail Family Transcriptional Repressor 1) • ANXA5 (Annexin A5)
    |
    bicalutamide
    5d
    Fluid Forces Control Structural Remodeling of Blind-Ended Lymphatic Microvessels. (PubMed, Adv Healthc Mater)
    The structural remodeling of these lymphatic vessels was concurrent with lymphangiogenesis. These results reveal how extravascular and intraluminal endothelial cells integrate signals from native fluid forces to coordinate the expansion and remodeling of capillary lymphatics.
    Journal
    |
    VEGFC (Vascular Endothelial Growth Factor C)
    10d
    TBC1D23 drives lymphatic metastasis in pancreatic ductal adenocarcinoma by altering EGFR cell surface dynamics and signaling. (PubMed, Cell Oncol (Dordr))
    These findings uncover TBC1D23 as a novel regulator of EGFR dynamics and a pivotal mediator of PDAC lymphatic metastasis. By delineating the TBC1D23/EGFR/VEGF-C signaling axis, this study not only identifies a promising biomarker for PDAC detection and prognosis but also highlights an actionable therapeutic target for intercepting metastatic progression.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • FLT4 (Fms-related tyrosine kinase 4) • VEGFC (Vascular Endothelial Growth Factor C)
    14d
    Improved Anticancer Properties of Silver Nanoparticles by Albumin Coating in Prostate Cancer Cell Lines: An In Vitro Study. (PubMed, Pharmaceutics)
    AgNPs-Alb significantly inhibited PC3 cell migration compared to AgNPs (p < 0.001) and Bicalutamide (p < 0.0001)...Additionally, a significant increase in P53 and E-cadherin, alongside a decrease in VEGF-C expression in LnCAP cells, was observed (p < 0.05). This study suggests that AgNPs-Alb have stronger anticancer and cytotoxic effects compared to AgNPs alone against PCa cell lines and higher effects were observed on PC3 cells compared to LnCAP cells.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • BAX (BCL2-associated X protein) • VEGFC (Vascular Endothelial Growth Factor C) • SNAI1 (Snail Family Transcriptional Repressor 1) • ANXA5 (Annexin A5)
    |
    bicalutamide
    14d
    miR-374b-5p Modulates Melanoma Progression by Targeting VEGFC and Regulating MAPK Signaling in the Tumor Microenvironment. (PubMed, Int J Mol Sci)
    In a mouse model, miR-374b-5p overexpression significantly reduced tumor growth and angiogenesis, and downregulated the lymphangiogenic factor VEGFC. Together, these findings identify miR-374b-5p as a novel regulator of melanoma progression that acts through VEGFC-associated MAPK signaling and tumor microenvironment reprogramming, identifying miR-374b-5p as a promising therapeutic candidate for melanoma.
    Journal
    |
    VEGFC (Vascular Endothelial Growth Factor C) • MIR374B (MicroRNA 374b)
    1m
    Interleukin-30 promotes melanoma spreading and triggers LAG-3 expression and T cell exhaustion. (PubMed, Biomed Pharmacother)
    Concurrently, IL30 suppresses T cell function by reducing CD25 and HLA-DR expression on CD4⁺ and CD8⁺ T cells, inhibiting their activation and proliferation, decreasing TNF-α and IFN-γ production, and boosting LAG-3 expression, which strongly correlates with IL30 levels in clinical samples. Collectively, these findings identify IL30 as a critical driver of melanoma dissemination and T cell exhaustion, providing a mechanistic link to immune resistance and failure of combination immunotherapies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • CD276 (CD276 Molecule) • TNFA (Tumor Necrosis Factor-Alpha) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • MMP2 (Matrix metallopeptidase 2) • VEGFC (Vascular Endothelial Growth Factor C) • LGALS3 (Galectin 3) • L1CAM (L1 cell adhesion molecule) • SNAI2 (Snail Family Transcriptional Repressor 2) • ITGB1 (Integrin Subunit Beta 1) • LGALS9 (Galectin 9)
    1m
    M2 macrophages promote lymphatic metastasis by regulating PKM2 nuclear translocation in triple-negative breast cancer. (PubMed, Cell Death Dis)
    Serum analysis in an independent TNBC cohort confirmed elevated TGF-β levels in LNM-positive versus LNM-negative patients. Our findings identify PKM2 as a driver of M2 macrophage-induced VEGFC/D overexpression and lymphatic metastasis, highlighting its therapeutic potential for TNBC patients with high LNM risk.
    Journal
    |
    VEGFC (Vascular Endothelial Growth Factor C) • TGFB1 (Transforming Growth Factor Beta 1) • PKM (Pyruvate Kinase M1/2)
    2ms
    Lymphatic metastasis of papillary thyroid carcinoma: mechanism and clinicopathological physiology. (PubMed, Front Endocrinol (Lausanne))
    Despite the frequency of lymphatic metastasis, its prognostic impact varies: microscopic nodal disease has minimal effect on survival, while macroscopic or extranodal extension increases recurrence and mortality risks. This synthesis of current evidence aims to guide clinicians in optimizing detection, treatment, and surveillance for PTC patients with lymphatic metastasis.
    Review • Journal
    |
    BRAF (B-raf proto-oncogene) • FLT4 (Fms-related tyrosine kinase 4) • VEGFC (Vascular Endothelial Growth Factor C)
    |
    BRAF V600E • BRAF V600
    2ms
    FomA-Containing Outer Membrane Vesicles of Fusobacterium Nucleatum Facilitate Bladder Cancer Lymphatic Metastasis via IL-6-Dependent M2b Macrophage Polarization. (PubMed, Adv Sci (Weinh))
    Furthermore, we identified pinocembrin, a natural flavonoid, as a potent inhibitor of the FomA-TLR2 interaction, effectively suppressing BCa progression. Collectively, our findings uncover a previously unrecognized microbiota-driven mechanism by which F. nucleatum-derived OMVs reprogram the tumor immune microenvironment toward a pro-metastatic state and highlight FomA as a promising therapeutic target.
    Journal • IO biomarker
    |
    IL6 (Interleukin 6) • VEGFC (Vascular Endothelial Growth Factor C) • TLR2 (Toll Like Receptor 2)
    2ms
    Metal-Supramolecular Drug Delivery System Empowered Meningeal Lymphatic Vessels-Bridged Intracranial-Peripheral Dual Immune Modulation for Reversing Glioblastoma Immune Suppression. (PubMed, Adv Sci (Weinh))
    Using coordination-driven self-assembly of lipoic acid (LA), iron ions (Fe3+), and bovine albumin (BSA), we engineered nanoassemblies with Verubecestat (MK-8931) encapsulated and with vascular endothelial growth factor C (VEGF-C) and c(RGDfK) conjugated...This MLVs-bridged intracranial-peripheral dual immunomodulation strategy effectively transforms immunologically "cold" GBM into "hot" tumors, resulting in potent tumor eradication and significantly prolonged survival in orthotopic GBM models. It not only presents a novel paradigm for synergistic GBM immunotherapy but also provides an alternative brain drug delivery approach.
    Journal
    |
    VEGFC (Vascular Endothelial Growth Factor C)
    2ms
    Adipocyte-driven STAT3-ANGPT2-PTGIS axis promotes cutaneous metastasis in breast cancer and represents a targetable pathway. (PubMed, NPJ Precis Oncol)
    Elevated STAT3, ANGPT2, and PTGIS levels correlated with reduced progression-free and disease-free survival. These findings highlight STAT3-mediated signaling and metabolic reprogramming as key drivers of CMBC progression and suggest a promising therapeutic target for this understudied and clinically challenging condition.
    Journal
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • VEGFC (Vascular Endothelial Growth Factor C) • PTGIS (Prostaglandin I2 Synthase)
    2ms
    An integrative genomic analysis of angiogenesis in hepatocellular carcinoma: from canonical drivers to emerging biomarkers. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    The translational-level expression was analyzed using the IHC section images from the Human Protein Atlas (HPA) database. Thus, targeting these factors for therapy, diagnosis, or prognosis could be a key strategies in the field of oncology.
    Journal
    |
    KDR (Kinase insert domain receptor) • IL6 (Interleukin 6) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • MMP2 (Matrix metallopeptidase 2) • FGF2 (Fibroblast Growth Factor 2) • VEGFC (Vascular Endothelial Growth Factor C) • MMP9 (Matrix metallopeptidase 9)